Dacomitinib Production Cost Reports

The report provides a detailed analysis essential for establishing a dacomitinib production plant. It encompasses all critical aspects necessary for dacomitinib production, including the cost of dacomitinib production, dacomitinib plant cost, dacomitinib production costs, and the overall dacomitinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a dacomitinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Dacomitinib is a targeted anticancer medicine that is mainly used in the medical treatments for specific types of lung cancer. It is primarily prescribed for patients with non-small cell lung cancer that has specific epidermal growth factor receptor (EGFR) mutations, such as exon 19 deletions or exon 21 L858R substitutions. The drug works by blocking signals that help cancer cells grow and spread. It finds its main application as a first-line treatment for patients whose cancer has spread to other parts of the body. It also supports treatment plans when a steady, once-daily therapy is needed to control symptoms like coughing or chest discomfort linked to lung tumours. Moreover, it is also used as a part of personalised cancer therapy when genetic testing confirms the presence of suitable EGFR mutations. It is often used in research studies to explore its potential in other cancers, including epithelial ovarian cancer.

The market for dacomitinib is primarily driven by its demand as an antineoplastic agent for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. Its application as a targeted cancer medicine to treat certain types of non-small cell lung cancer that carry specific EGFR gene changes significantly fuels its demand in the pharmaceutical industry. Its demand in oncology centres for the treatment plans aimed at improving survival and slowing disease progression further supports its market expansion.

Its role in providing a steady oral therapy for patients who need long-term cancer management further contributes to growing market demand. Progress in synthesis methods, dependable suppliers, safe handling measures, and efficient distribution networks also influence global procurement, as manufacturers and healthcare providers prioritise consistent supply for uninterrupted treatments. Industrial dacomitinib procurement is also shaped by the cost and availability of specialised starting materials, strict regulatory requirements, and quality standards linked to advanced oncology drugs.

Raw Material for Dacomitinib Production

According to the dacomitinib production plant project report, the major raw materials for dacomitinib production include nitroarene, aniline, butenoic acid, and acetic acid.

Production Process of Dacomitinib

The extensive dacomitinib production cost report consists of the following industrial production process:

1. Production via Chemical Synthesis: The production process of dacomitinib begins with the hydrogenation of a nitroarene to form an aniline derivative that is carried straight into the next step without cleanup. Then, this aniline is joined with a butenoic acid intermediate through an amidation reaction, followed by a careful alkaline quench and a cooling crystallisation that forms the main amide. To avoid issues with handling poorly soluble quinazoline intermediates, the quinazoline ring system is built only at the end. Then, the amide intermediate undergoes a Dimroth rearrangement with another aniline component in acetic acid under carefully controlled mild conditions to construct the quinazoline core of dacomitinib. After quenching, neutralising, and a final seeded crystallisation, dacomitinib is obtained as the final product.

Dacomitinib is a second-generation, selective, and irreversible tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) family. It appears as a white to pale yellow powder. The molecular formula of the compound is C24H25ClFN5O2, and its molar mass is 469.94 g/mol. It is soluble in dimethyl sulfoxide (DMSO) and dimethylformamide (DMF) but has limited aqueous solubility. It has a melting point in the range of 184-187 degrees Celsius, and its boiling point is around 665.7 degrees Celsius. The compound is marketed under the brand name Vizimpro. The compound is a known toxicant, and it is harmful if swallowed or absorbed through the skin. It is recommended to wear protective clothing while handling the compound. Extended exposure to this substance may cause serious adverse effects such as skin rash, exfoliative skin reactions, diarrhoea, hepatotoxicity, and interstitial lung disease. The compound is also known to cause embryofetal toxicity.